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INTRODUCTION
Mantle cell lymphoma (MCL) is one of the most aggressive lymphoid neoplasms. 1 This biological behavior has been attributed to the molecular mechanisms involved in its pathogenesis combining the deregulation of cell proliferation, disruption of the DNA damage response pathways and the activation of cell survival mechanisms. SOX11 belongs to the SOX gene family encoding for transcription factors which play a critical role in the regulation of cell fate and differentiation in major developmental processes. In mice, Sox11 is important in organ development and neurogenesis. 8, 9 SOX11 upregulation has been detected in various types of human solid tumors. 10, 11 SOX4, the SOX family member with the highest homology to SOX11, is a prominent transcription factor in lymphocytes of both B-and T-cell lineage 12 and is crucial for B-cell lymphopoiesis. 13 In contrast, SOX11 has no known lymphopoietic function and it is neither expressed in lymphoid progenitors nor in mature normal Bcells. However, it is expressed in virtually all aggressive MCL, and at lower levels in a subgroup of Burkitt and acute lymphoblastic lymphomas but not in other lymphoid Six MCL cell lines, five SOX11 positive (Z138, GRANTA519, REC1, HBL2 and JEKO1) and one SOX11 negative (JVM2) 17 were used for ChIP-chip and/or ChIPqPCR experiments, gene expression analysis after SOX11 silencing, and WB experiments. Human Embryonic Kidney 293 (HEK293) cells were used for luciferase assays.
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MATERIALS AND METHODS
Cell lines and patient samples
Microarray GEP data previously generated in 38 primary MCL, 16 SOX11-positive and 22 SOX11-negative, were used for GSEA (GSE36000).
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Immunophenotypic surface markers were investigated in six of these primary MCL, 3
SOX11-positive and 3 negative, by flow cytometry. 
ChIP-quantitative-PCR
Primers for the qPCR analysis of the SOX11 ChIP-enriched genomic DNA regions were designed using Primer3 (http://frodo.wi.mit.edu/) (Table S1 ). Amplified SOX11-ChIP DNA and 1:100 diluted input samples were analyzed in triplicate by qRT-PCR using Fast SYBR ®Green Master Mix in a StepOnePlus PCR detection system (Applied Biosystems, Foster City, CA).
Reporter plasmid constructs and luciferase assay
The SOX11-binding site from the regulatory region of PAX5 gene (ChIP-peak region from -2435pb to -1884pb) was amplified by PCR using GRANTA519 genomic DNA and primers listed in Table S1 . Subsequently, the PCR fragment was cloned in front of a minimal promoter luciferase reporter vector pGL4. 
Gene Expression Profiling
Total RNA of Z138 cells stably transduced with short hairpins targeting SOX11 and control short hairpin was extracted with the TRIzol reagent following the 
Gene Set Enrichment Analysis (GSEA)
We performed GSEA 18 on two pre-ranked lists of genes derived from in vitro SOX11 silencing microarray data and from our series of 38 purified primary MCL data.
To generate these pre-ranked lists we analyzed the GEP of our in vitro cell line model as well as the GEP of 38 primary MCL according to their SOX11 expression levels.
Details on GSEA are provided on Supplemental Materials and Methods. 
SOX11 silencing by lentiviral infection
qRT-PCR
qRT-PCR was performed as described before 19 using a designed primer set and TaqMan ® MGB probe for SOX11 using Primer Express ® Software Version 2.0 (Applied Biosystems) (primers used are shown in Table S1 ). Inventoried TaqMan® Gene Expression Assays were used for:
(Hs01547250_m1), LCK (Hs00178427_m1). Relative quantification of gene expression was analyzed with the 2 -ΔΔCt method using GUS (Hs00939627_m1) as the endogenous control.
Flow cytometry studies
For immunophenotype analysis, 500,000 cells of interest were collected in 1.5mL tubes, washed once in PBS-0.5% BSA and stained with 5μL of antibody against For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
Immunohistochemical staining
Immunohistochemical studies were performed as previously described 16, 20 
Statistical analysis
Data are represented as mean ± SD of three independent experiments. Statistical tests were performed using SPSS v16.0 software (SPSS). Comparison between two groups of samples was evaluated by independent sample t test, and results were considered statistically significant when P-val<0.05.
RESULTS
Genome-wide promoter analysis of SOX11 in MCL
We first investigated the direct target genes of SOX11 using ChIP and DNA microarrays (ChIP-chip). We used a MCL cell line with high SOX11 expression (Z138) and one negative for SOX11 (JVM2) ( Figure 1A ). ChIP was performed using a SOX11 specific antibody ( Figure S1 ). ChIP-enriched DNA sequences were amplified and hybridized to a high-resolution DNA tiling array spanning promoter regions of the whole human genome. These experiments identified 5842 significant enriched peaks belonging to 1133 unique genes (SOX11-bound genes) that were consistently enriched in immunoprecipitated material across all three independent Z138 replicates after subtracting the corresponding non-specific immunoprecipitated material in JVM2 (Table S2 ).
The promoter region of SOX11 was not identified in this analysis. We have reported that SOX11 expression is associated with active histone marks. 19 We have now observed a significant reduction in the enrichment of the activating histone mark
H3K4me3 at the SOX11 promoter upon SOX11 silencing ( Figure S2 ), suggesting that SOX11 may regulate indirectly its own expression by epigenetic mechanisms.
Gene ontology (GO) term enrichment analysis showed several biological processes overrepresented in the SOX11-bound genes, including transcription, embryonic and neuronal development, cell growth and proliferation, cell death and apoptosis, cell cycle, hematopoiesis and hematological system development and function ( Figure 1B ).
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Differential gene expression profiling after SOX11 silencing
To determine the transcriptional programs regulated by SOX11 we generated a MCL cellular model by silencing SOX11 expression (Figure 2A ). We then compared the GEP of stably transduced shSOX11 and shControl Z138 cells ( Figure 2B , Table S3 ).
The top annotated functions of the differentially expressed genes included lymphocyte activation and differentiation, phosphorylation, cell cycle, immune system development and hematopoiesis ( Figure 2C ). A GSEA using the genes differentially expressed in primary SOX11-positive and negative MCL confirmed that the GEP observed in our in vitro model was representative of that observed in these primary MCL (Table S4 , Figure S3 ).
Interestingly, among the significant differentially expressed genes between shSOX11 and shControl cells we observed up-regulation of key regulators of plasma cell differentiation and pronounced down-regulation of B-cell genes. To further characterize the significance of these changes, we performed a GSEA using welldefined gene signatures related to the different steps of the mature B-cell and plasma cell differentiation programs (Table S4) . [21] [22] [23] [24] These analyses showed that the GEP of 
SOX11 directly regulates the transcription of PAX5
To determine the direct targets transcriptionally regulated by SOX11, we overlaid the list of SOX11-bound genes and those with differential expression upon
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SOX11 knockdown and found 147 genes in common. From these 147 genes, 18 genes still overlapped using more stringent statistical criteria (P-val<0.05 and log2 fold change (FC)>0.7) ( Figure 2D , Table S6 ).
Interestingly, among these 18 genes we identified PAX5, an essential transcription factor regulating B-cell identity in early B-cell development 25 and late Bcell differentiation, 26 as one of the highest confident SOX11-bound genes (False Discovery Rate (FDR)<0.1 and Peak Score (PS)≥0.5). We also found genes that can contribute to SOX11 hematopoietic and B-cell activation functions (MSI2 and HSPD1, respectively).
We then verified the direct binding of SOX11 to the regulatory regions of the most significantly overlaid genes by ChIP-qPCR in Z138 and GRANTA519 MCL cell lines. As expected, no binding within these regulatory regions was detected in the SOX11-negative JVM2 ( Figure 3A) . Downregulation of PAX5 in stable SOX11
knockdown MCL cell lines was confirmed by qRT-PCR and WB ( Figure 3B -C, respectively). Upregulation of MSI2, HSPD1, SUV39H2 and SEPT2 was also observed but in a much lesser extent than PAX5, prompting us to focus on the SOX11-PAX5 relationship.
To verify the transcriptional effect of SOX11 on the PAX5 promoter, the amplified SOX11 ChIPed-PAX5 fragment ( Figure S5 ) was cloned in front of a minimal promoter luciferase reporter and tested in transient co-transfections with SOX11 expression vector. The induction in luciferase activity was detected in the co-expression with SOX11 but not with SOX4 or truncated SOX11 proteins lacking the HMG domain (ΔHMGSOX11) or the C-terminal TAD domain (ΔTADSOX11) ( Figure 3D ), both required for its transcriptional activity. 27, 28 These findings demonstrate the specificity of SOX11 in regulating the transcription of PAX5.
For
SOX11-knockdown MCL cell lines display early plasmacytic differentiation
PAX5 is the critical transcription factor that determines and maintains B-cell identity by activating the expression of B-cell specific genes and simultaneously repressing genes that promote plasma cell differentiation. 25, 26 The Figure 5C and Figure S6D ). The Ki-67 proliferation index and phospho-histone H3 were similar in control and silenced tumors ( Figure S7A ). We did not observe significant changes in cell density, proliferation, cycle phases or viability after SOX11 silencing in cell lines in culture ( Figure S7B-E) . However, in vivo SOX11-silenced tumors had large necrotic areas with high levels of activated cleaved caspase-3 that were minimal or not observed in SOX11-positive tumors ( Figure 5D and Figure   S6D ). These results suggest that SOX11 sustains the B-cell differentiation program and tumor cell survival in vivo and support the implication of SOX11 expression in the aggressive behavior of these tumors.
SOX11 expression and B-cell differentiation program in primary tumors
We next investigated whether SOX11 modulation of the mature B-cell and early plasmacytic differentiation programs observed in vitro also occurred in primary cells from SOX11-positive and negative MCL tumors.
We first investigated whether the expression of the SOX11-bound genes was modulated in MCL. GSEA analysis showed a statistically significant enrichment of SOX11 high confident bound genes identified by ChIP-chip (Table S2) in both Z138shControl and primary SOX11-positive MCL ( Figure S8 ), indicating that in these models SOX11 significantly activates the expression of its target genes.
We then defined two gene sets related to SOX11 transcriptional program extracted from our in vitro microarray data, SOX11-upregulated genes (genes downregulated upon SOX11 silencing) and SOX11-downregulated genes (upregulated upon knockdown) (Table S4) . Notably, we found that SOX11-positive primary MCL ).
Conversely, SOX11-negative primary MCL presented an enrichment in SOX11-downregulated genes (NES=-2.10, FDR<10 -4 ) ( Figure 6A ).
These results suggest that the SOX11 transcriptional program derived from our knockdown experiments is also observed in primary tumors prompting us to evaluate whether the modulation of B-cell and plasmacytic differentiation programs also occurs in these primary tumors.
We thus performed a GSEA with gene signatures of the different steps of the mature B-cell and plasma cell differentiation programs used in our previous analysis (Table S4) 
DISCUSSION
In this study we have used a ChIP-chip approach to reveal the first human genome-wide promoter analysis of SOX11 and identified 1133 unique genes as putative targets of this transcription factor in MCL. Using GEP, we have also identified 366 genes whose expression was modulated by silencing SOX11 in MCL cell lines. GO analyses identified that genes regulated by SOX11 in these lymphoid cells were involved in lymphocyte activation and differentiation, phosphorylation, cell cycle, immune system development, hematopoiesis and lymphoid organ development as the top annotated functions, but also in stem cell development, apoptosis and cell migration.
The role of different members of the SOX gene family, including SOX11, as direct regulators of an expression program of early neural lineage development has been recently recognized in a murine model. 34 Our ChIP-chip study confirmed SOX11
binding to regulatory regions of similar genes involved in neuronal development (BTG2, MEIS1, and NR2E1) but these genes were not expressed in our lymphoid model indicating the tissue specific regulation of the SOX11-bound genes. In our study, the main target genes modulated by SOX11 were involved in immune system development and hematopoiesis, being PAX5, MSI2 and HSPD1 among the most significant genes directly regulated by SOX11.
The significant shift from a mature B-cell to a plasmacytic gene expression program identified by GSEA in our SOX11 knockdown cells was highly suggestive of a major effect of the direct modulation of PAX5 by SOX11 in these tumor cells. We have demonstrated here that PAX5 is a direct target gene regulated by SOX11 and the constitutional expression of SOX11 in these tumors maintains the downstream PAX5
program. Thus, several B-cell specific genes directly activated by PAX5 were downregulated in SOX11-knockdown MCL cell lines whereas BLIMP1 was SOX11 is constitutively overexpressed in the vast majority of MCL. [14] [15] [16] However, recent studies have identified a subset of SOX11-negative MCL 4 36 The significance of blocking plasma cell differentiation program as a relevant oncogenic mechanism in lymphoid neoplasias has been previously observed. The impairment of terminal B-cell differentiation caused by SOX11 overexpression in MCL may parallel the forced expression of PAX5 by the t(9;14)(p13;q32) translocation identified in some B-cell lymphomas, [37] [38] [39] and the inactivating mutations of PRDM1 in diffuse large B-cell lymphomas. [40] [41] [42] In summary, our study reveals the global transcriptional network and direct target genes regulated by SOX11 in MCL that may contribute to the development and aggressive behavior of this tumor. Our findings provide an improved understanding of the molecular mechanisms contributing to the pathogenesis of MCL and may have clinical implications in the diagnosis of patients and selection of therapeutic strategies more adapted to the molecular diversity of this tumor.
ACCESSION NUMBERS
All microarray data are available at the Gene Expression Omnibus (National (A) The expression levels of SOX11 protein in different MCL cell lines (JVM2, REC1, GRANTA519, JEKO1, HBL2 and Z138) were detected by WB using an anti-SOX11
antibody (H-290).
α -tubulin was used as a loading control.
(B) IPA functional annotation tool related to the high confidence SOX11-bound genes.
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